Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 0.50 |
| ▸ | PPARA | Q07869 | 12/20 | 0.50 |
| ▸ | PPARD | Q03181 | 5/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.43 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 2/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4341706 | 0.99 | PPARG (0.51) | PPARGPPARAPPARDMCHR1LDHA | |
| SCHEMBL4338050 | 0.84 | PPARG (0.50) | PPARGPPARAPPARD | |
| SCHEMBL4346276 | 0.84 | PPARA (0.55) | PPARGPPARAPPARDLDHAMMP1 | |
| SCHEMBL4337259 | 0.83 | PPARG (0.52) | PPARGPPARAPPARD | |
| SCHEMBL4341834 | 0.82 | PPARA (0.53) | PPARGPPARAPPARDLDHAMMP1 | |
| SCHEMBL5550663 | 0.82 | PPARG (0.50) | PPARGPPARAPPARD | |
| SCHEMBL4334772 | 0.82 | PPARA (0.59) | PPARGPPARAPPARDLDHAMMP1 | |
| SCHEMBL5556259 | 0.81 | PPARG (0.51) | PPARGPPARAPPARD | |
| SCHEMBL5380853 | 0.79 | PPARG (0.59) | PPARGPPARAPPARD | |
| SCHEMBL14437953 | 0.79 | PPARG (0.51) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | PPARG 379/4885PPARA 339/4885PPARD 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.